Evidence map›Paper›PMID 26916412›Full record

ReviewCancer2016

Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco.

Lisa M Fucito, Sharon Czabafy, Peter S Hendricks, Chris Kotsen, Donna Richardson, Benjamin A Toll, Association for the Treatment of Tobacco Use and Dependence/Society for Research on Nicotine and Tobacco Synergy Committee

Open access · bronzeAbstract readReview
In one paragraph

Review in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 4 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 4 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018
    Guideline
  3. Guideline
  4. Pooled it
  5. Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Updates in Lung Cancer Screening: A Decade of Evidence.Seminars in respiratory and critical care medicine · 2025
    Review
  16. Lung Cancer Screening in the Incarcerated Population Through a Community Imaging Partnership.Journal of correctional health care : the official journal of the National Commission on Correctional Health Care · 2025
    Article
  17. Article
  18. Review
  19. Current Evidence for a Lung Cancer Screening Program.Portuguese journal of public health · 2024
    Review
  20. Barriers and Facilitators to Engaging in Smoking Cessation Support Among Lung Screening Participants.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024
    Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Lisa M FucitoDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Sharon CzabafyWellspan Ephrata Community Hospital Wellness Center, Stevens, Pennsylvania.
Peter S HendricksDepartment of Human Behavior, School of Public Health, University of Alabama, Birmingham, Alabama.
Chris KotsenTobacco Quitcenter, Lung Cancer Institute, Steeplechase Cancer Center, Robert Wood Johnson University Hospital Somerset, Somerville, NJ.
Donna RichardsonTobacco Dependence Program, Cancer Institute of New Jersey, School of Public Health, Robert Wood Johnson Medical School at Rutgers, New Brunswick, New Jersey.
Benjamin A TollDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Association for the Treatment of Tobacco Use and Dependence/Society for Research on Nicotine and Tobacco Synergy Committee
Johnson University · USMUSC Hollings Cancer Center · USSomerset Medical Center · USUniversity of Alabama · USWellSpan Ephrata Community Hospital · USYale Cancer Center · US

Funding

Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Roy S Herbst · 2015 to 2026
$31.1M
New Approaches to Smoking Cessation in Heavy DrinkersK23AA020000 · NIAAA · YALE UNIVERSITY · PI FUCITO, LISA M · 2011 to 2016
$755k
Novel Treatment to Enhance Smoking Cessation before Cancer SurgeryR21CA181569 · NCI · YALE UNIVERSITY · PI TOLL, BENJAMIN ANDREW · 2014 to 2015
$438k
NCI NIH HHS P50 CA196530NCI NIH HHS P50CA196530NCI NIH HHS R21 CA181569NCI NIH HHS R21CA181569NIAAA NIH HHS K23 AA020000NIAAA NIH HHS K23AA020000
6 · The paper itself

Abstract

Smoking cessation is crucial for reducing cancer risk and premature mortality. The US Preventive Services Task Force (USPSTF) has recommended annual lung cancer screening with low-dose computed tomography (LDCT), and the Center for Medicare and Medicaid Services recently approved lung screening as a benefit for patients ages 55 to 77 years who have a 30 pack-year history. The Society for Research on Nicotine and Tobacco (SRNT) and the Association for the Treatment of Tobacco Use and Dependence (ATTUD) developed the guideline described in this commentary based on an illustrative literature review to present the evidence for smoking-cessation health benefits in this high-risk group and to provide clinical recommendations for integrating evidence-based smoking-cessation treatment with lung cancer screening. Unfortunately, extant data on lung cancer screening participants were scarce at the time this guideline was written. However, in this review, the authors summarize the sufficient evidence on the benefits of smoking cessation and the efficacy of smoking-cessation interventions for smokers ages 55 to 77 years to provide smoking-cessation interventions for smokers who seek lung cancer screening. It is concluded that smokers who present for lung cancer screening should be encouraged to quit smoking at each visit. Access to evidence-based smoking-cessation interventions should be provided to all smokers regardless of scan results, and motivation to quit should not be a necessary precondition for treatment. Follow-up contacts to support smoking-cessation efforts should be arranged for smokers. Evidence-based behavioral strategies should be used at each visit to motivate smokers who are unwilling to try quitting/reducing smoking or to try evidence-based treatments that may lead to eventual cessation.

Indexed as

Early Detection of CancerAdvisory CommitteesEvidence-Based MedicineFemaleHumansLung NeoplasmsMaleMedicaidMedicarePractice Guidelines as TopicProgram EvaluationSmokingSmoking CessationTobacco Use DisorderTomography, X-Ray ComputedUnited Statescigarette smokinglung cancer screening preventionsmoking cessationtobacco

Identifiers

PMID26916412
PMCPMC4828323
OpenAlexW2284770678

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.